

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for the Leipzig Interventional Course (LINC) features the letters 'L I N C' in a bold, blue, sans-serif font. The letters are arranged horizontally with significant spacing between them. Behind the letters is a large, abstract graphic consisting of several overlapping, curved, brushstroke-like shapes in shades of blue and grey, creating a sense of motion and depth.

Sahil Parikh

Page 1/3

Wednesday, January 27, 2021

MAIN ARENA 1

- 19:00 – 20:20** **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**
MODERATOR:
Dierk Scheinert
Peter Schneider
PANEL:
Andrew Holden
Marianne Brodmann
Robert Lookstein
- 19:00 – 19:03 Introduction by the moderators
Dierk Scheinert
Peter Schneider
- 19:03 – 19:08 Insights on paclitaxel safety from the femoral-popliteal RCTs
Peter Schneider
- 19:08 – 19:13 Insights on paclitaxel safety from femoral-popliteal real-world data
Eric Secemsky
- 19:13 – 19:21 New insights from the interim safety analysis of the SWEDEPAD study
Joakim Nordanstig
- 19:21 – 19:26 How does the Voyager data help us understand the risks of paclitaxel?
Marc Bonaca
- 19:26 – 19:31 Paclitaxel safety in patients with CLTI
Marianne Brodmann
- 19:31 – 19:36 Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications
Robert Lookstein
- 19:36 – 19:41 New data on paclitaxel in the next couple of years; what should we expect?
Eva Freisinger
- 19:41 – 19:49 Panel discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Sahil Parikh

Page 2/3

Wednesday, January 27, 2021

- | | |
|---------------|---|
| 19:49 – 19:54 | Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?
Sahil Parikh |
| 19:54 – 19:59 | Previous experience with limus compounds in the non-coronary arteries; lessons learned
Thomas Zeller |
| 19:59 – 20:04 | New limus delivering devices for above and below knee occlusive disease; when to expect results?
Andrew Holden |
| 20:04 – 20:14 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?
Dierk Scheinert |
| 20:14 – 20:20 | Panel discussion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Sahil Parikh

Page 3/3

Thursday, January 28, 2021

MAIN ARENA 2

- 09:15 – 10:15** **Is Sirolimus emerging as a potential future treatment strategy in PAD over Paclitaxel?**
partially supported by Concept Medical
CHAIRMAN:
Nils Kucher
MODERATOR:
Dierk Scheinert
PANEL:
Konstantinos Katsanos
Francesco Liistro
Tjun Tang
- 09:15 – 09:23 Overcoming Paclitaxel with Sirolimus in PAD
Konstantinos Katsanos
- 09:23 – 09:45 Live case transmission from Sengkang General Hospital, Singapore
Edward Choke
- 09:45 – 09:55 Why Sirolimus coated balloons are a better option for PAD and AVF interventions
Aloke Finn
- 09:55 – 10:03 Assessing unmet needs in lower extremity interventions: Sirolimus eluting technologies
Sahil Parikh
- 10:03 – 10:15 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.